A second death has occurred in a clinical trial in China using gene editing technology to treat rare diseases. A young boy suffering from Duchenne muscular dystrophy died after an immune response following treatment, marking the second such case following the death of a six-year-old last month. The treatment company, HuiDaGene, reported the death according to relevant regulations but said that specific details would be released in a future paper. This incident has raised concerns about the safety and information disclosure practices surrounding gene therapy research in China.
